Case todayBrokenLate SEC filing · Nov 18, 2026The case · holding · Nov 22, 2026Own CTSO if ICU and cardiac-surgery adoption expands fast enough to outrun cash burn and financing risk.5 conditions2 strengthening · 3 holdingNext resultsFeb 4, 2027Projected from its filing dates

CTSO at a glance

The past year

Chart

+584.3% $4.37, close Nov 20

From the highest close
−31.8%
Vs the 200-day average
+164.6%
Nov 19, 2025Daily close, CytosorbentsNov 20, 2026

Short interest

History

134,896 shares

Since the last report
+17.9%
Days to cover
1.1 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 16 – Nov 22

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

CTSO price history

Latest price$4.16Today−$0.97 (-18.91%)
CTSO -27.34%S&P 500 -10.82%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Clinicians and hospitals continue to find Cytosorbents’ blood-purification approach useful in ICU and cardiac-surgery workflows, so demand behaves like recurring acute-care consumable utilization rather than fading trial demand.HoldingMateriality: High

    FY2025 GAAP annual revenue was $37.063 million, up from $35.595 million in FY2024. If adoption persists, even a small company can compound revenue through recurring cartridge use; if protocols move away, the revenue base has little protection.

    Watch: Critical-care or cardiac-surgery guideline committees decline to recommend hemoadsorption because trials fail to show sufficient patient benefit.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 GAAP annual revenue was $37.063 million, up from $35.595 million in FY2024.

    Open source ↗
  • The disposable medical-device model retains enough pricing power, mix benefit, and manufacturing efficiency to keep blood-purification sales structurally high margin despite small company scale.StrengtheningMateriality: High

    FY2025 GAAP annual gross profit was $26.491 million on $37.063 million of revenue, implying an approximately 71.5% gross margin. High gross margins are the economic foundation for any eventual operating leverage; if tenders or competition compress pricing, growth would not translate into value.

    Watch: European tenders, hospital purchasing groups, or distributors force lower cartridge prices to win volume.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 GAAP annual gross profit was $26.491 million on $37.063 million of revenue, implying an approximately 71.5% gross margin.

    Open source ↗
  • Management’s reduced spending base gives the business a credible path to operating leverage if adoption expands, rather than requiring revenue growth to be purchased with uncontrolled R&D and commercial expense.HoldingMateriality: Medium

    FY2025 GAAP annual operating loss was $14.749 million, improved from a $16.452 million loss in FY2024. Owners need growth to become self-funding; if spending must re-accelerate just to defend the franchise, gross margin will not reach shareholders.

    Watch: A new pivotal trial, post-market study, or FDA remediation program requires a major rebuild of R&D spending.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 GAAP annual operating loss was $14.749 million, improved from a $16.452 million loss in FY2024.

    Open source ↗
  • The company remains financing-dependent, so strategic capital, faster commercialization, or a sharp burn reduction is needed to prevent creditors or new equity from capturing too much of the upside.StrengtheningMateriality: Medium

    Cash was $6.249 million at December 31, 2025. Even if the technology works, shareholders can lose if the company must raise capital on unfavorable terms before reaching scale.

    Watch: A strategic partner, distributor, or acquirer provides non-dilutive capital or a meaningful upfront payment.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $6.249 million at December 31, 2025.

    Open source ↗
  • The upside case depends on blood-purification use broadening beyond the current niche into larger cardiac-surgery or ICU protocols, because the existing revenue base is not yet large enough to absorb the public-company, regulatory, and commercial cost structure.HoldingMateriality: Medium

    FY2025 GAAP net loss was $8.198 million despite $37.063 million of GAAP revenue. Without a larger addressable use case, CTSO may remain a high-gross-margin but structurally loss-making microcap device company.

    Watch: FDA or other regulators reject, delay, or narrow a cardiac-surgery or antithrombotic-removal indication.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 GAAP net loss was $8.198 million despite $37.063 million of GAAP revenue.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Clinicians and hospitals continue to find Cytosorbents’ blood-purification approach useful in ICU and cardiac-surgery workflows, so demand behaves like recurring acute-care consumable utilization rather than fading trial demand. If adoption persists, even a small company can compound revenue through recurring cartridge use; if protocols move away, the revenue base has little protection.

The disposable medical-device model retains enough pricing power, mix benefit, and manufacturing efficiency to keep blood-purification sales structurally high margin despite small company scale. High gross margins are the economic foundation for any eventual operating leverage; if tenders or competition compress pricing, growth would not translate into value.

Management’s reduced spending base gives the business a credible path to operating leverage if adoption expands, rather than requiring revenue growth to be purchased with uncontrolled R&D and commercial expense. Owners need growth to become self-funding; if spending must re-accelerate just to defend the franchise, gross margin will not reach shareholders.

The company remains financing-dependent, so strategic capital, faster commercialization, or a sharp burn reduction is needed to prevent creditors or new equity from capturing too much of the upside. Even if the technology works, shareholders can lose if the company must raise capital on unfavorable terms before reaching scale.

The upside case depends on blood-purification use broadening beyond the current niche into larger cardiac-surgery or ICU protocols, because the existing revenue base is not yet large enough to absorb the public-company, regulatory, and commercial cost structure. Without a larger addressable use case, CTSO may remain a high-gross-margin but structurally loss-making microcap device company.

All standing thesis claims
Original report summary

ICU and cardiac-surgery adoption expands fast enough to outrun cash burn and financing risk.

Evidence assessed Nov 22, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Cytosorbents

Where the evidence on Cytosorbents stands: Holding on the latest evidence (Nov 22, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.

Bull case: what the evidence supports

  • Clinicians and hospitals continue to find Cytosorbents’ blood-purification approach useful in ICU and cardiac-surgery workflows, so demand behaves like recurring acute-care consumable utilization rather than fading trial demand.

    sec.gov ↗

  • The disposable medical-device model retains enough pricing power, mix benefit, and manufacturing efficiency to keep blood-purification sales structurally high margin despite small company scale.

    sec.gov ↗

  • Management’s reduced spending base gives the business a credible path to operating leverage if adoption expands, rather than requiring revenue growth to be purchased with uncontrolled R&D and commercial expense.

    sec.gov ↗

  • The company remains financing-dependent, so strategic capital, faster commercialization, or a sharp burn reduction is needed to prevent creditors or new equity from capturing too much of the upside.

    sec.gov ↗

  • The upside case depends on blood-purification use broadening beyond the current niche into larger cardiac-surgery or ICU protocols, because the existing revenue base is not yet large enough to absorb the public-company, regulatory, and commercial cost structure.

    sec.gov ↗

Bear case: what would count against it

  • Critical-care or cardiac-surgery guideline committees decline to recommend hemoadsorption because trials fail to show sufficient patient benefit.

    sec.gov ↗

  • European tenders, hospital purchasing groups, or distributors force lower cartridge prices to win volume.

    sec.gov ↗

  • A new pivotal trial, post-market study, or FDA remediation program requires a major rebuild of R&D spending.

    sec.gov ↗

Thesis-Break Engine

What has broken in Cytosorbents’s thesis

Each break OptimistFi flagged on Cytosorbents, dated — with what has historically followed the same kind of break across the market, not a forecast for Cytosorbents.

peers+16%-43%-12%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -12% path vs comparable companies over six months, inside the middle-half range (+16% to -43%). A base rate, not a forecast.
  • Late SEC filingcondition set before this filing

    Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Entered a material definitive agreement.

    Cytosorbents filed an SEC 8-K on 2026-11-20: Entered a material definitive agreement. It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    Cytosorbents filed an SEC 8-K on 2026-11-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Regulation FD disclosure.

    Cytosorbents filed an SEC 8-K on 2026-09-23: Regulation FD disclosure. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Critical-care or cardiac-surgery guideline committees decline to recommend hemoadsorption because trials fail to show sufficient patient benefit.
  • European tenders, hospital purchasing groups, or distributors force lower cartridge prices to win volume.
  • A new pivotal trial, post-market study, or FDA remediation program requires a major rebuild of R&D spending.
  • A strategic partner, distributor, or acquirer provides non-dilutive capital or a meaningful upfront payment.
  • FDA or other regulators reject, delay, or narrow a cardiac-surgery or antithrombotic-removal indication.

CTSO news

Loading headlines…

Financial statements

CTSO income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

CTSO: quick answers

When does Cytosorbents (CTSO) report earnings next?
Cytosorbents's next results are projected for February 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 12, 2026. Earnings calendar
What is CTSO's short interest?
As of October 30, 2026, 134,896 CTSO shares were sold short, up 17.9% from the count before. At the stock's average daily volume that is 1.1 days to cover. FINRA publishes the count twice a month. CTSO short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.